News ArticleBosch Limited Publishes Public Notice on Loss of Share Certificates on November 4, 2026
Notice published in The Business Line to inform about lost share certificates, ensuring regulatory compliance and stakeholder awareness
Bosch Limited issued a public notice in The Business Line newspaper on November 4, 2026, to inform about the loss of share certificate(s) and requested stakeholders to take note. This regulatory procedure is part of maintaining transparency regarding share certificate losses.
Bosch Limited
General / Other
Bosch Limited announced the loss of share certificate(s) through an official public notice published on November 4, 2026, in The Business Line newspaper, addressing its shareholders and stakeholders.
The notice is published as per Regulation 47 of SEBI's Listing Obligations and Disclosure Requirements (2015) to maintain transparency and inform stakeholders about the loss of specific share certificates.
The announcement was formally communicated to the stock exchanges — BSE and NSE — and is part of the company’s corporate compliance and governance practices.
This announcement does not include details on the specific certificates lost but serves as a notification to shareholders and relevant parties for vigilance and record correction if necessary.
Highlights
- Loss of share certificate(s) notified on November 4, 2026.
- Notice published in The Business Line newspaper (English edition).
- Compliance with SEBI Regulation 47 under Listing Obligations and Disclosure Requirements.
- Applicable to Bosch Limited with stock codes BSE:500530 and NSE:BOSCHLTD.
- Communication signed by V. Srinivasan, Company Secretary and Compliance Officer.
Key Data Snapshot
What happened
- Bosch Limited issued a public notice on November 4, 2026, regarding the loss of share certificate(s).
- The notice was published in The Business Line newspaper (English edition) as part of compliance with SEBI regulations.
Regulatory and governance context
- The announcement aligns with SEBI Listing Obligations and Disclosure Requirements (2015), Regulation 47.
- The notice serves to alert shareholders and related parties about the lost share certificate(s), supporting transparent corporate governance.
- Such notices are standard practice to prevent fraudulent transactions or confusion related to lost share certificates.
Background and context
- Bosch Limited is a Bengaluru headquartered company with stock codes BSE:500530 and NSE:BOSCHLTD.
- The Company Secretary & Compliance Officer, V. Srinivasan, was designated to communicate and sign this notice.
- No details regarding the numbers or numbers of lost certificates were disclosed in the notice.
Highlights
- Loss of share certificate(s) notified on November 4, 2026.
- Notice published in The Business Line newspaper (English edition).
- Compliance with SEBI Regulation 47 under Listing Obligations and Disclosure Requirements.
- Applicable to Bosch Limited with stock codes BSE:500530 and NSE:BOSCHLTD.
- Communication signed by V. Srinivasan, Company Secretary and Compliance Officer.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulation 47, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
